Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00299546 · ClinicalTrials.gov registry record · Phase 3
A Study of the Safety and Efficacy of Golimumab (CNTO 148) in Subjects With Active Rheumatoid Arthritis Previously Treated With Biologic Anti-TNFa Agent(s)
A Phase 3 study, sponsored by Centocor.
- Completed
- Registry status
- Phase 3
- Development phase
- 461
- Enrollment target
NCT00299546 is a Phase 3 study that has completed, run by Centocor. The registered enrollment target is 461 participants.
The verdict
NCT00299546, a Phase 3 study, has completed, sponsored by Centocor.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 461 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of golimumab (CNTO 148) in subjects who have active rheumatoid arthritis and have been treated previously with at least 1 dose of a biologic anti-TNFa agent (etanercept, adalimumab or infliximab).
Interventions
- DRUG Placebo
- BIOLOGICAL Golimumab 100 mg
- BIOLOGICAL Golimumab 50 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 461 participants |
| Start Date | 2006-02 |
| Est. Completion | 2012-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00299546
The ClinicalTrials.gov registry entry for NCT00299546 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 461 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Centocor, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00299546 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00299546 about?
NCT00299546 is a clinical study titled "A Study of the Safety and Efficacy of Golimumab (CNTO 148) in Subjects With Active Rheumatoid Arthritis Previously Treated With Biologic Anti-TNFa Agent(s)". The purpose of this study is to evaluate the efficacy and safety of golimumab (CNTO 148) in subjects who have active rheumatoid arthritis and have been treated previously with at least 1 dose of a biologic anti-TNFa agent (etanercept, adalimumab or infliximab).
What is the current status of trial NCT00299546?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 461 participants. The study started on 2006-02. Estimated completion is 2012-05.
What interventions are being tested in trial NCT00299546?
The interventions under investigation include: Placebo (DRUG), Golimumab 100 mg (BIOLOGICAL), Golimumab 50 mg (BIOLOGICAL).
Who is sponsoring clinical trial NCT00299546?
This trial is sponsored by Centocor, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.